Active	Status	Sponsor type	Region	Phase	Filter
4 Active 8 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kaplan, Lawrence D
CALGB-50403, NCT00310037: Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma ICML 2013 Jun 2013 - Jun 2013: ICML 2013	Active, not recruiting	2	151	US	bortezomib	Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc.	Mantle Cell Lymphoma	12/13
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL From TRANSCEND-CLL-004 trial in CLL at ASH 2019 Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019 Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL Presentation of P1 data from P1/2 trial for CLL at ASH 2018 Dec 2018 - Dec 2018: Presentation of P1 data from P1/2 trial for CLL at ASH 2018 From TRANSCEND-CLL-004 trial in CLL at ASH 2018 [screenshot] Dec 2018 - Dec 2018: From TRANSCEND-CLL-004 trial in CLL at ASH 2018 [screenshot] More	Recruiting	1/2	320	Canada, US	JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax	Juno Therapeutics, a Subsidiary of Celgene	Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic	11/27	11/27